Page last updated: 2024-09-02

fingolimod hydrochloride and Coronavirus Infections

fingolimod hydrochloride has been researched along with Coronavirus Infections in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	14 (100.00)	2.80

Authors

Authors	Studies
Robertson, NP; Willis, MD	1
Bussone, G; Louapre, C; Lubetzki, C; Maillart, E; Papeix, C; Pourcher, V; Roux, T	1
Barzegar, M; Khorvash, F; Maghzi, AH; Mirmosayyeb, O; Nehzat, N; Sarrafi, R; Shaygannejad, V	1
Adam, EH; Bauer, B; Foerch, C; Friedauer, L; Wolf, T	1
Valencia-Sanchez, C; Wingerchuk, DM	1
Bowen, JD; Brink, J; Brown, TR; Lucassen, EB; Repovic, P; Smoot, K; Wundes, A	1
Azimi, AR; Nourbakhsh, B; Safavi, F	1
Diaz, V; Guevara, C; Naves, R; Rosas, CS; Villa, E	1
Amor, S; Baker, D; Giovannoni, G; Kang, AS; Schmierer, K	1
Badolato, R; Capra, R; Chiarini, M; Giacomelli, M; Imberti, L; Moratto, D; Paghera, S; Rossi, N	1
Filippi, M; Preziosa, P; Rocca, MA	1
Bergamaschi, R; Fabbro, BD; Mallucci, G; Zito, A	1
Ghobrial, RM; Kloc, M	1
Ahmed, SF; Alroughani, R; Ibrahim Ismail, I; Salama, S	1

Reviews

1 review(s) available for fingolimod hydrochloride and Coronavirus Infections

Article	Year
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Multiple sclerosis and related disorders, 2020, Volume: 43 Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines	2020

Article

Year

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.

Multiple sclerosis and related disorders, 2020, Volume: 43

Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines

2020

Other Studies

13 other study(ies) available for fingolimod hydrochloride and Coronavirus Infections

Article	Year
Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. Journal of neurology, 2020, Volume: 267, Issue:5 Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus	2020
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum. Revue neurologique, 2020, Volume: 176, Issue:6 Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurology(R) neuroimmunology & neuroinflammation, 2020, Volume: 7, Issue:4 Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Multiple sclerosis and related disorders, 2020, Volume: 42 Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Deprescriptions; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Noninvasive Ventilation; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed	2020
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. Multiple sclerosis and related disorders, 2020, Volume: 42 Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; C-Reactive Protein; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Deprescriptions; Female; Ferritins; Fibrin Fibrinogen Degradation Products; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Interleukin-6; L-Lactate Dehydrogenase; Lymphopenia; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index	2020
COVID-19 in MS: Initial observations from the Pacific Northwest. Neurology(R) neuroimmunology & neuroinflammation, 2020, 09-03, Volume: 7, Issue:5 Topics: Adult; Aged; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunocompromised Host; Immunosuppressive Agents; Interferons; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Northwestern United States; Nursing Homes; Oregon; Pandemics; Pneumonia, Viral; Severity of Illness Index; Toluidines; Travel; Washington	2020
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Multiple sclerosis and related disorders, 2020, Volume: 43 Topics: Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Disease Susceptibility; Dyspnea; Epidemics; Female; Fever; Fingolimod Hydrochloride; Glatiramer Acetate; Hospitalization; Humans; Hydroxybutyrates; Immunocompromised Host; Immunologic Factors; Intensive Care Units; Interferons; Iran; Lung; Lymphocyte Depletion; Male; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severity of Illness Index; Toluidines; Tomography, X-Ray Computed	2020
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations. Multiple sclerosis and related disorders, 2020, Volume: 43 Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chile; Coronavirus Infections; COVID-19; Decision Making; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Guideline Adherence; Guidelines as Topic; Health Behavior; Humans; Immunologic Factors; Interferons; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pandemics; Pneumonia, Viral; Quarantine; SARS-CoV-2; World Health Organization; Young Adult	2020
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection. Journal of neuroimmunology, 2020, 08-15, Volume: 345 Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; SARS-CoV-2	2020
COVID-19 will change MS care forever - No. Multiple sclerosis (Houndmills, Basingstoke, England), 2020, Volume: 26, Issue:10 Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Disease Management; Drug Substitution; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Telemedicine; Viral Vaccines	2020
Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod. Multiple sclerosis and related disorders, 2020, Volume: 45 Topics: Adult; Asymptomatic Diseases; Betacoronavirus; Coronavirus Infections; COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome	2020
The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients. Multiple sclerosis and related disorders, 2020, Volume: 45 Topics: Azetidines; Benzyl Compounds; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; rhoA GTP-Binding Protein; SARS-CoV-2	2020
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care. Clinical neurology and neurosurgery, 2020, Volume: 197 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Child; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunologic Factors; Interferon-beta; Kuwait; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Recurrence; Rituximab; SARS-CoV-2; Surveys and Questionnaires; Telephone; Toluidines; Young Adult	2020